Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216885 · ClinicalTrials.gov registry record · NA
Solv Multi-Pass Hemodialysis System In-Center Clinical Study
A NA study of End Stage Renal Disease, sponsored by Medtronic - MITG.
- Recruiting
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT07216885: Recruiting NA study of End Stage Renal Disease, sponsored by Medtronic - MITG.
NCT07216885 is a NA study of End Stage Renal Disease that is actively recruiting participants, run by Medtronic - MITG. The registered enrollment target is 46 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07216885, a NA study of End Stage Renal Disease, is actively recruiting participants, sponsored by Medtronic - MITG.
- RECRUITING
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and/or ultrafiltration. Eligibility will be open to incident dialysis patients and patients currently receiving HD in an in-center environment. All vascular access types including AV-fistula, AV-graft, and tunneled hemodialysis catheters.
Primary Outcome
Evaluate the number of serious device-related adverse events that occur during the In-Center Phase of the study, to confirm there are no additional risks associated with the Solv System implementation of sorbent-based HD.
Conditions Studied
Interventions
- DEVICE Solv Multi-Pass Hemodialysis System
Study Locations (1)
South Carolina
- Carolina Nephrology - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT07216885 shows while recruiting
NCT07216885 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Solv Multi-Pass Hemodialysis System is the first listed.
NCT07216885 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT07216885 about?
NCT07216885 is a clinical study titled "Solv Multi-Pass Hemodialysis System In-Center Clinical Study". Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and/or ultrafiltration. Eligibility will be open to incident dialysis patients and ...
What is the current status of trial NCT07216885?
This trial is currently recruiting. It is a NA study. The enrollment target is 46 participants. The study started on 2026-01-13. Estimated completion is 2026-07.
What conditions does trial NCT07216885 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT07216885?
The interventions under investigation include: Solv Multi-Pass Hemodialysis System (DEVICE).
Who is sponsoring clinical trial NCT07216885?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216885 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07216885's enrollment target sits among peer trials
46 53rd of 86 higher than 34 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
RECRUITING · NA
-
CAPABLE Transplant
RECRUITING · NA
-
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI